ALNY

What's Next For Alnylam Stock After The Recent Positive Development For Intellia?

Alnylam's (ALNY) NDA For Vutrisiran Gets FDA Acceptance

What's Next For Alnylam Stock After The Recent 22% Rise?

Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)

Alnylam's (ALNY) Q1 Loss Narrower Than Expected, Revenues Beat

Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q1 2021 Results - Earnings Call Transcript

Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran